XML 84 R71.htm IDEA: XBRL DOCUMENT v3.22.1
BALANCE SHEETS - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 23,236,000 $ 15,598,000
Total current assets 32,641,000 47,455,000
Total assets 42,215,000 52,989,000
Current liabilities    
Accrued expenses 2,366,000 551,000
Total current liabilities 4,405,000 2,088,000
Total liabilities 23,028,000 7,454,000
Commitments and Contingencies
Stockholders' (Deficit) Equity    
Additional paid-in capital [1] 18,063,000 17,140,000
Accumulated deficit (52,840,000) (25,569,000)
Total shareholders' deficiency [1] (34,777,000) (8,429,000)
Total liabilities, convertible preferred shares and shareholders' deficiency 42,215,000 52,989,000
CIK 0001822935 Healthcare Capital Corp    
Current assets    
Cash and cash equivalents 556,494  
Total current assets 556,494  
Deferred offering costs   165,029
Marketable securities held in Trust Account 275,016,417  
Total assets 275,572,911 165,029
Current liabilities    
Accrued expenses 893,937 1,374
Accrued offering costs   50,175
Due to related parties   89,854
Total current liabilities 893,937 141,403
Deferred underwriting fee payable 10,325,000  
Warrant liability 10,137,500  
Total liabilities 21,356,437 141,403
Class A common stock, $.0001 par value; 100,000,000 shares authorized; 27,500,000 and no shares subject to possible redemption issued and outstanding at redemption value at December 31, 2021 and 2020, respectively 275,000,000  
Stockholders' (Deficit) Equity    
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 6,875,000 and 6,900,000 shares issued and outstanding at December 31, 2021 and 2020, respectively 687 690
Additional paid-in capital   24,310
Accumulated deficit (20,784,213) (1,374)
Total shareholders' deficiency (20,783,526) 23,626
Total liabilities, convertible preferred shares and shareholders' deficiency $ 275,572,911 $ 165,029
[1] Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March 7, 2022. See also note 10, Shareholders’ Deficiency, for details.